CN104164403B - 一种提取及培养脂肪干细胞的方法 - Google Patents
一种提取及培养脂肪干细胞的方法 Download PDFInfo
- Publication number
- CN104164403B CN104164403B CN201410360143.3A CN201410360143A CN104164403B CN 104164403 B CN104164403 B CN 104164403B CN 201410360143 A CN201410360143 A CN 201410360143A CN 104164403 B CN104164403 B CN 104164403B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- fat
- culture
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000012258 culturing Methods 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract description 41
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 21
- 210000001519 tissue Anatomy 0.000 claims abstract description 12
- 230000029087 digestion Effects 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims abstract description 3
- 239000012531 culture fluid Substances 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 229940088598 enzyme Drugs 0.000 claims description 17
- 241000190633 Cordyceps Species 0.000 claims description 10
- 210000002249 digestive system Anatomy 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 210000000496 pancreas Anatomy 0.000 claims description 10
- 239000003855 balanced salt solution Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 102000012422 Collagen Type I Human genes 0.000 claims description 6
- 108010022452 Collagen Type I Proteins 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 235000003969 glutathione Nutrition 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000013517 stratification Methods 0.000 claims description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000004140 cleaning Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 abstract 2
- 238000010009 beating Methods 0.000 abstract 1
- 238000007664 blowing Methods 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 63
- 230000006698 induction Effects 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 230000002188 osteogenic effect Effects 0.000 description 8
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 5
- 102100022464 5'-nucleotidase Human genes 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102100037241 Endoglin Human genes 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 5
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 5
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 5
- 102100032818 Integrin alpha-4 Human genes 0.000 description 5
- 102100025304 Integrin beta-1 Human genes 0.000 description 5
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 230000002293 adipogenic effect Effects 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- -1 CD31 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CIZVQWNPBGYCGK-UHFFFAOYSA-N benzenediazonium Chemical group N#[N+]C1=CC=CC=C1 CIZVQWNPBGYCGK-UHFFFAOYSA-N 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- KQSBZNJFKWOQQK-UHFFFAOYSA-N hystazarin Natural products O=C1C2=CC=CC=C2C(=O)C2=C1C=C(O)C(O)=C2 KQSBZNJFKWOQQK-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 229940033816 solvent red 27 Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
分组 | 胰酶-EDTA(%) | I型胶原酶(%) | IV型胶原酶(%) |
实施例2 | 0.15 | 0.15 | 0.3 |
实施例3 | - | 0.7 | 0.3 |
实施例4 | 2.5 | 0.75 | - |
实施例5 | 0.05 | 0.05 | 0.5 |
实施例6 | 实施例7 | 实施例8 | 实施例9 | 实施例10 | |
L-谷氨酰胺(mmol/L) | 2 | 3 | 5 | 6 | 0.5 |
bFGF(ng/ml) | 20 | 30 | 35 | 10 | 5 |
EGF(ng/ml) | 10 | - | 20 | 25 | 15 |
LIF(ng/ml) | 10 | 25 | - | 15 | 1 |
谷胱甘肽(μg/ml) | 10 | 3 | 5 | 20 | 35 |
虫草提取物(μg/ml) | 50 | 50 | 50 | 50 | 50 |
细胞密度(1×106) | |
对照培养基 | 2.2 |
实施例1 | 23.8 |
实施例6 | 22.9 |
实施例7 | 5.6 |
实施例8 | 8.4 |
实施例9 | 15.2 |
实施例10 | 14.3 |
虫草提取物含量(μg/ml) | 细胞密度(1×106) | |
实施例11 | - | 10.9 |
实施例12 | 25 | 15.7 |
实施例13 | 75 | 14.3 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410360143.3A CN104164403B (zh) | 2014-07-25 | 2014-07-25 | 一种提取及培养脂肪干细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410360143.3A CN104164403B (zh) | 2014-07-25 | 2014-07-25 | 一种提取及培养脂肪干细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104164403A CN104164403A (zh) | 2014-11-26 |
CN104164403B true CN104164403B (zh) | 2017-04-12 |
Family
ID=51908385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410360143.3A Active CN104164403B (zh) | 2014-07-25 | 2014-07-25 | 一种提取及培养脂肪干细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104164403B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104498433B (zh) * | 2014-11-28 | 2018-01-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种脂肪干细胞的提取方法以及制剂和应用 |
TWI696701B (zh) * | 2015-10-08 | 2020-06-21 | 高雄醫學大學 | 一種快速分離脂肪間質細胞之組合物 |
WO2017059566A1 (zh) * | 2015-10-08 | 2017-04-13 | 高雄医学大学 | 一种快速分离脂肪间质细胞的组合物 |
CN106222134A (zh) * | 2016-07-29 | 2016-12-14 | 中卫华医(北京)生物科技有限公司 | 高效获取脂肪间充质干细胞的培养方法 |
CN106047702B (zh) * | 2016-08-15 | 2018-07-20 | 北京昱龙盛世生物科技有限公司 | 一种用于培养脂肪干细胞的试剂盒及培养方法 |
CN106350483A (zh) * | 2016-10-14 | 2017-01-25 | 中卫华医(北京)生物科技有限公司 | 诱导脂肪间充质干细胞向软骨细胞分化的培养方法 |
CN106399236A (zh) * | 2016-11-28 | 2017-02-15 | 广东万海细胞生物科技有限公司 | 一种促进脂肪干细胞生长的培养方法 |
CN107557331B (zh) * | 2017-09-15 | 2020-04-10 | 上海莱馥医疗科技有限公司 | 一种分离和培养人脂肪干细胞的方法 |
CN107714727A (zh) * | 2017-10-24 | 2018-02-23 | 成都远山博桥生物科技有限公司 | 一种浓缩脂肪干细胞培养上清制剂、其制备方法及应用 |
CN109988747A (zh) * | 2017-12-30 | 2019-07-09 | 西安洛威塔生物科技有限责任公司 | 一种脂肪来源的脂肪干细胞的分离扩增方法及其应用 |
CN108753708B (zh) * | 2018-06-20 | 2019-05-10 | 廊坊康宝汇泰生物技术有限公司 | 一种干细胞活性因子冻干粉的制备方法 |
CN108753712B (zh) * | 2018-07-04 | 2022-11-01 | 成都清科生物科技有限公司 | 一种脂肪干细胞提取方法 |
CN109097325A (zh) * | 2018-08-01 | 2018-12-28 | 丁彬彬 | 一种用于美容保养的脂肪干细胞液的制备方法 |
CN109554339A (zh) * | 2018-12-29 | 2019-04-02 | 中国医学科学院整形外科医院 | 一种从脂肪抽吸物中高效分离脂肪间充质干细胞的方法 |
CN110343661B (zh) * | 2019-04-24 | 2021-08-24 | 朗姿赛尔生物科技(广州)有限公司 | 一种人体脂肪干细胞的提取及培养扩增方法 |
CN110484499A (zh) * | 2019-09-18 | 2019-11-22 | 安徽科门生物科技有限公司 | 一种脂肪干细胞的提取及培养方法 |
CN110862960A (zh) * | 2019-11-12 | 2020-03-06 | 武汉济源高科技有限公司 | 一种新型脂肪干细胞培养方法 |
CN111040994A (zh) * | 2019-11-20 | 2020-04-21 | 中国人民解放军陆军军医大学第一附属医院 | 一种高效分离脂肪来源脂肪间充质干细胞的方法 |
CN112831465A (zh) * | 2021-01-12 | 2021-05-25 | 上海南滨江细胞生物科技有限公司 | 用于治疗中枢神经系统损伤的自体脂肪源干细胞的培养方法 |
CN112708597A (zh) * | 2021-01-14 | 2021-04-27 | 上海南滨江细胞生物科技有限公司 | 用于治疗退行性关节炎的自体外周血干细胞的培养方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101984049B (zh) * | 2010-12-09 | 2012-11-21 | 协和干细胞基因工程有限公司 | 从脂肪组织中分离间充质干细胞的方法 |
CN102757936B (zh) * | 2012-06-15 | 2013-10-23 | 江苏瑞思坦生物科技有限公司 | 人脂肪干细胞增殖促进剂及其应用方法 |
CN103667187B (zh) * | 2012-09-12 | 2016-05-18 | 贵州神奇集团控股有限公司 | 一种人脂肪干细胞的分离培养方法和干细胞库的构建方法 |
CN103849597A (zh) * | 2012-12-05 | 2014-06-11 | 上海坤爱生物科技有限公司 | 脂肪干细胞的规模化生产工艺 |
-
2014
- 2014-07-25 CN CN201410360143.3A patent/CN104164403B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104164403A (zh) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104164403B (zh) | 一种提取及培养脂肪干细胞的方法 | |
CN107236704B (zh) | 从胎盘分离间充质干细胞的方法和使用的消化酶组合物 | |
CN102127522B (zh) | 人脐带间充质干细胞及其制备方法 | |
CN101914490B (zh) | 一种人羊膜间充质干细胞无血清培养基及其培养方法 | |
CN102676451B (zh) | 从胎盘中分离间充质干细胞的方法 | |
CN102807966B (zh) | 胎盘全细胞冻存、复苏以及分离和扩增干细胞的方法 | |
CN102002475B (zh) | 人脂肪成体干细胞的获取方法及该干细胞库的构建方法 | |
CN107299082B (zh) | 从组织中分离胎盘间质细胞并培养成间充质干细胞的方法 | |
US11098280B2 (en) | Serum-free culture medium and preparation method and application therefor | |
CN109234229B (zh) | 从胎盘血管分离间充质干细胞的方法和所用消化酶组合物 | |
CN107653225A (zh) | 一种用于扩增人间充质干细胞的培养基及其扩增方法 | |
CN104357387A (zh) | 一种从人脂肪组织中分离人脂肪干细胞的方法 | |
CN102028970A (zh) | 一种用于治疗肝硬化的干细胞制剂 | |
CN104694464A (zh) | 一种临床用牙髓干细胞及其制备方法 | |
CN107557331A (zh) | 一种分离和培养人脂肪干细胞的方法 | |
CN105850979A (zh) | 一种骨髓间充质干细胞的冻存保护液及冻存方法 | |
CN108486050A (zh) | 从犬的脐带制备间充质干细胞的方法 | |
CN109628388B (zh) | 用消化酶组合物从胎盘血管分离间充质干细胞 | |
CN106119191A (zh) | 一种胎盘绒毛板间充质干细胞及临床化制备方法 | |
CN110846273A (zh) | 一种脂肪组织来源的间充质干细胞培养及三系分化诱导方法 | |
CN105062960B (zh) | 一种牙周膜干细胞原代分离及培养方法 | |
CN106834217A (zh) | 一种促进人羊膜上皮细胞体外扩增的方法及应用 | |
CN113774020B (zh) | 一种脂肪间充质干细胞库的构建方法 | |
CN113287603B (zh) | 一种生物样本保存液及其制备方法与应用 | |
CN113201491B (zh) | 一种促进干细胞体外增殖和分化的培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231020 Address after: 611130 5 / F and 6 / F, building 11, 733, Section 2, Furong Avenue, Yongning Town, Wenjiang District, Chengdu City, Sichuan Province Patentee after: Cel Thomas Biotechnology (Chengdu) Co.,Ltd. Address before: Room 802, Building C, Qingwang Science and Technology Park, Baohe Economic Development Zone, Hefei City, Anhui Province, 230041 Patentee before: Hefei xingzhicheng Information Technology Co.,Ltd. Effective date of registration: 20231020 Address after: Room 802, Building C, Qingwang Science and Technology Park, Baohe Economic Development Zone, Hefei City, Anhui Province, 230041 Patentee after: Hefei xingzhicheng Information Technology Co.,Ltd. Address before: 116622 Dalian University, 10, Xuefu Avenue, Dalian economic and Technological Development Zone, Liaoning Patentee before: DALIAN University |
|
TR01 | Transfer of patent right |